SOUTH PLAINFIELD, N.J., Dec. 19 /PRNewswire/ -- PTC Therapeutics, Inc.
(PTC), a biopharmaceutical company focused on the discovery, development, and
commercialization of small-molecule drugs targeting post-transcriptional
control mechanisms, today named David P. Southwell to its Board of Directors.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )
"Mr. Southwell brings additional broad-based biopharmaceutical expertise
to PTC's Board of Directors," stated Dr. Stuart Peltz, President and Chief
Executive Officer of PTC Therapeutics. "In particular, his extensive
financial knowledge, as it relates to life sciences, will be of great value as
PTC enters new stages of growth. We are honored and delighted that he has
decided to join PTC's Board of Directors."
Mr. Southwell has been Executive Vice President and Chief Financial
Officer of Sepracor Inc., a research-based pharmaceutical company dedicated to
the treatment and prevention of human disease, since June 1994. During Mr.
Southwell's tenure, Sepracor and its subsidiaries have raised approximately
$3.0 billion in three equity and nine convertible financings, and the
Company's market capitalization has risen from $70 million to approximately $6
billion. Prior to joining Sepracor, Mr. Southwell was a Vice President in
investment banking with Lehman Brothers in New York. His career at Lehman
spanned 10 years, and included mergers, acquisitions, leveraged buyouts,
restructurings, and debt and equity financing transactions. While at Lehman,
he managed the IPO of Sepracor in September 1991.
"I am honored to join the distinguished Board of Directors at this dynamic
company," said Mr. Southwell. "PTC's approach to small-molecule drug
discovery addresses major, intractable disorders and the management team has
laid an outstanding foundation for success. I look forward to working with
PTC's Board and team to accomplish the goals that lie ahead."
Mr. Southwell holds a BA from Rice University and an MBA from the Tuck
School at Dartmouth College. Mr. Southwell is Chairman of the Board of
BioSphere Medical and serves on the Board of the MBA Advisory Board of the
Tuck School.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development,
and commercialization of small-molecule drugs targeting post-transcriptional
control mechanisms. Post-transcriptional control processes are the sequence
of events in the cell that ultimately regulate the rate and timing of all
protein production. PTC discovers and develops small molecule drugs that
alter these processes by selectively modulating how RNA is used to produce
proteins. This approach enables PTC to advance its drug discovery programs
rapidly from targets to preclinical and clinical drug candidates, building a
pipeline across genetic disorders, oncology, and infectious diseases.
Jane Baj
PTC Therapeutics, Inc.
(908) 222-7000, x167
jbaj@ptcbio.com
Robert Stanislaro
Noonan Russo
(212) 845-4268
robert.stanislaro@eurorscg.com
SOURCE PTC Therapeutics, Inc.
 back to top
Related links:
http://www.ptcbio.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO
CONTACT:
Jane Baj of PTC Therapeutics, Inc.,
+1-908-222-7000 ext. 167, jbaj@ptcbio.com; or Robert Stanislaro
of Noonan Russo, +1-212-845-4268, robert.stanislaro@eurorscg.com
|
